Home > Journals > Journal of Neurosurgical Sciences > Past Issues > Articles online first > Journal of Neurosurgical Sciences 2017 Nov 20



To subscribe PROMO
Submit an article
Recommend to your librarian


Publication history
Cite this article as



Journal of Neurosurgical Sciences 2017 Nov 20

DOI: 10.23736/S0390-5616.17.04077-2


language: English

Primary gliosarcoma: epidemiology, clinical presentation, management and survival

Ruichong MA, Delia-Marina ALEXE, Davide BOERIS, Erlick PEREIRA

Department of Neurosurgery, Oxford University Hospitals, Oxford, UK


Gliosarcomas are malignant tumours of the central nervous system. As glioblastomas (GBM), they are treated in a similar fashion. However there is growing evidence to suggest that they may be a separate entity. Due to the rarity of primary gliosarcomas (PGS)Here we publish single centre data over a 14-year period, comprising possibly one of the biggest case series in the literature to our knowledge. The mean age at presentation was 59 years with male preponderance (1.75:1). The most common presenting symptoms were balance and mobility issues (61%), followed by headaches (50%) and visual problems (39%). Tumours were most likely to involve the frontal and parietal lobes (27% and 21% respectively). Patients under 50 had a significant survival advantage (50% versus 32%). All patients had surgery, 79% had adjuvant radiotherapy, with a further 21% also receiving chemotherapy. Median survival from surgery of patients diagnosed with PGS was 6.6 months. Median and one-year survival were significantly better for patients who received radiotherapy (14 months; 46% one year survival) and improved further with combined radioand chemotherapy (30 months; 77%, one year survival). For patients of good status, adjuvant chemo-radiotherapy is warranted and should be offered as it confers a muchimproved overall survival.

KEY WORDS: Primary Gliosarcoma - Glioblastoma

top of page